TY - JOUR T1 - Vitamin D Supplements for Prevention of Covid-19 or other Acute Respiratory Infections: a Phase 3 Randomized Controlled Trial (CORONAVIT) JF - medRxiv DO - 10.1101/2022.03.22.22271707 SP - 2022.03.22.22271707 AU - David A. Jolliffe AU - Hayley Holt AU - Matthew Greenig AU - Mohammad Talaei AU - Natalia Perdek AU - Paul Pfeffer AU - Sheena Maltby AU - Jane Symons AU - Nicola L. Barlow AU - Alexa Normandale AU - Rajvinder Garcha AU - Alex G. Richter AU - Sian E. Faustini AU - Christopher Orton AU - David Ford AU - Ronan A. Lyons AU - Gwyneth A. Davies AU - Frank Kee AU - Christopher J. Griffiths AU - John Norrie AU - Aziz Sheikh AU - Seif O. Shaheen AU - Clare Relton AU - Adrian R. Martineau Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/23/2022.03.22.22271707.abstract N2 - BACKGROUND Vitamin D metabolites support innate immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory pathogens. Randomized controlled trials of vitamin D to prevent coronavirus disease 2019 (Covid-19) have not yet reported.METHODS We randomly assigned 6200 U.K. adults to receive an offer of a postal finger-prick 25-hydroxyvitamin D (25[OH]D) test with provision of a 6-month supply of higher-dose vitamin D (3200 IU/d, n=1550) or lower-dose vitamin D (800 IU/d, n=1550) to those with blood 25(OH)D concentration <75 nmol/L, vs. no offer of testing or supplementation (n=3100). The primary outcome was the proportion of participants experiencing at least one swab test- or doctor-confirmed acute respiratory infection (ARI) of any cause at six months. Secondary outcomes included incidence of swab test-confirmed Covid-19.RESULTS Of 3100 participants offered testing, 2958 (95.4%) accepted, and 2690 (86.8%) had 25(OH)D <75 nmol/L and were sent vitamin D supplements (1356 higher-dose, 1334 lower-dose). 76 (5.0%) vs. 87 (5.7%) vs. 136 (4.6%) participants in higher-dose vs. lower-dose vs. no-offer groups experienced at least one ARI of any cause (odds ratio [OR] for higher-dose vs. no-offer 1.09, 95% CI 0.82-1.46; lower-dose vs. no-offer 1.26, 0.96-1.66). 45 (3.0%) vs. 55 (3.6%) vs. 78 (2.6%) participants in higher-dose vs. lower-dose vs. no-offer groups developed Covid-19 (OR for higher-dose vs. no-offer 1.13, 0.78-1.63; lower-dose vs. no-offer 1.39, 0.98-1.97).CONCLUSIONS Among adults with a high baseline prevalence of vitamin D insufficiency, implementation of a test-and-treat approach to vitamin D replacement did not reduce risk of all-cause ARI or Covid-19.TRIAL REGISTRATION ClinicalTrials.gov no. NCT04579640Competing Interest StatementThe CORONAVIT trial was supported by the following entities who manufacture or distribute vitamin D supplements and/or vitamin D-fortified foods: Pharma Nord Ltd, DSM Nutritional Products Ltd, Synergy Biologics Ltd, Cytoplan Ltd, Thornton & Ross Ltd, Warburtons Ltd, and Hyphens Pharma Ltd. ARM declares receipt of support from Abiogen Pharma Ltd and Pharma Nord Ltd to attend meetings and/or travel.Clinical TrialNCT04579640Funding StatementThis study was supported by Barts Charity (ref. MGU0459), Pharma Nord Ltd, the Fischer Family Foundation, DSM Nutritional Products Ltd, the Exilarchs Foundation, the Karl R Pfleger Foundation, the AIM Foundation, Synergy Biologics Ltd, Cytoplan Ltd, the UK National Institute for Health Research Clinical Research Network, the HDR UK BREATHE Hub, Thornton & Ross Ltd, Warburtons Ltd, Mr Matthew Isaacs (personal donation), and Hyphens Pharma Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Queens Square Research Ethics Committee, London, U.K. (ref 20/HRA/5095)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data will be provided on reasonable request to a.martineau{at}qmul.ac.uk subject to the terms of ethical approval and Sponsor requirements. ER -